Loading
BMS-986365 is an experimental protein degrader from Celgene in phase 3 trials for prostate cancer, aimed at Androgen receptor.
BMS-986365 is a protein degrader developed by Celgene. Its target is Androgen receptor (the sponsor names androgen receptor (AR)). The sponsor states: A dual androgen receptor ligand-directed degrader and antagonist, i.e. it both degrades the AR protein and blocks its activity. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06764485 (A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer), in prostate cancer. The largest, NCT06764485, plans to enrol 960 participants with primary completion expected 2027-09-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
A dual androgen receptor ligand-directed degrader and antagonist, i.e. it both degrades the AR protein and blocks its activity. Connects to Androgen receptor.
1.BMS-986365 binds Androgen receptor with one end and an E3 ubiquitin ligase with the other.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BMS-986365" OR ABSTRACT:"BMS-986365") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BMS-986365, not a curated reading list.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.